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Abstract 
Background: Solitary fibrous tumors (SFT) of the retroperitoneum are rare spindle cell neoplasms, with a paucity of 
data on treatment outcomes. We hypothesized that surgical excision offered acceptable outcomes in SFTs.
Methods: The National Cancer Database (NCDB) was used to identify patients with SFT from 2004 to 2011. Primary 
outcome measures were 30 day mortality and overall survival. Descriptive analyses were performed. Furthermore, a 
systematic review of published literature was conducted after creating a pre-specified search strategy.
Results: Of 51 patients in the NCDB, 58.8 % (n = 30) were males, with a median age 60 years (IQR 49–72 years). 
Median tumor size was 16 cm (IQR 11–21 cm). Surgical resection was performed in 92.2 % (n = 47) with 63.8 % 
(n = 30) having a margin negative resection. Peri-operative mortality was 2.1 % (n = 1). Of survival outcomes available 
for 18 patients, the median OS was 51.1 months. From the systematic review, we identified 8 studies, with 24 patients. 
Median age and tumor size was similar to the NCDB [47.5 years (IQR 39–66.5 years), 12 cm (IQR 7–17 cm)]. Majority 
[91.7 % (n = 22)] underwent surgical excision alone while one received adjuvant chemotherapy and none received 
radiation. After median follow up of 54 months (IQR 28–144 months), 79.2 % (n = 19) were alive without disease. 
Three patients (12.5 %) died of disease, one was alive with disease and one was lost to follow up. Recurrence was 
reported in 16.7 % (n = 4) of patients.
Conclusion: Complete surgical excision is a viable treatment modality for retroperitoneal SFT leading to long term 
survival. Low recurrence rates would argue against the need for routine adjuvant radiation or chemotherapy.
Keywords: Solitary fibrous tumors, Retroperitoneal sarcoma, Adjuvant chemotherapy, Adjuvant radiotherapy, 
Surgical outcomes, Surgical Oncology
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Background
Solitary fibrous tumors (SFT) are extremely rare spindle 
cell neoplasms with a varied presentation. First described 
as a pleural tumor by Klemperer et  al. later they were 
identified in extra-thoracic sites, most commonly the 
adrenals, head and neck, retroperitoneum, kidneys, liver 
and skeletal muscle [1–3]. Existing literature on SFTs 
are limited to case reports that mostly describe pleural 
tumors [4, 5]. Owing to its rarity, extra-pleural SFTs have 
not been studied adequately.
Retroperitoneal SFTs are a distinct sub-group of 
extra-pleural SFTs, often incidentally discovered dur-
ing imaging for an unrelated pathology and present with 
non-specific symptoms, mainly abdominal pain, hip pain 
and urinary symptoms [6]. Extra-thoracic SFTs have been 
classically described as benign tumors but recent studies 
with larger numbers of cases and longer follow up have 
demonstrated the existence of a subgroup of tumors that 
exhibit a malignant clinical course with local and distant 
recurrence even after surgical excision [4, 7, 8]. Adverse 
outcomes are usually associated with atypical histologi-
cal features (nuclear pleomorphism, increased cellular-
ity, necrosis or mitoses greater than 4/10 HPF) and size 
greater than 10 cm [9, 10]. Also, cases of extra-thoracic 
SFTs with benign features at initial presentation have 
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been reported to recur years after surgical excision with 
malignant features [9, 11, 12].
Surgical excision has been the standard treatment 
option for both benign and malignant SFTs but late 
recurrences have been observed [2, 13]. A multi-modality 
approach using adjunct radiotherapy and chemotherapy 
has been utilized in cases where complete excision is not 
achieved [14]. We hypothesized that surgical excision 
is an acceptable treatment modality with favorable out-
comes for SFTs of retroperitoneal origin.
Methods
The National Cancer Database (NCDB) was surveyed 
for cases with a histological diagnosis of solitary fibrous 
tumors from 2004 to 2011. The NCDB was established in 
1989 as a joint project of the American Cancer Society and 
the Commission on Cancer of the American College of 
Surgeons. It is a nationwide, facility-based, comprehensive 
clinical surveillance resource oncology data set that cap-
tures 70 % of all newly diagnosed malignancies in the US 
annually, covering more than 1500 commission-accredited 
cancer programs (http://www.ncdbpuf.facs.org). Cases 
diagnosed at autopsy were excluded. Demographic details, 
tumor characteristics, treatment and follow-up data were 
abstracted from the database. Primary outcome measures 
were 30-day mortality and overall survival. Descriptive sta-
tistical analysis was performed.
A systematic review of published literature on SFTs 
was conducted in the MEDLINE database using Pub-
Med using a pre-specified search strategy (Fig. 1). Search 
terms used were “solitary fibrous tumor” and “retroperi-
toneum”. Case reports and literature published in non-
English languages were excluded from the study. The 
search strategy returned 55 articles and 8 studies satis-
fied the selection criteria. Bibliographies of the selected 
articles were further searched but no additional relevant 
articles were found. All the selected articles were retro-
spective cohort studies.
Statistical analysis was performed using Stata Software 
Version 12.1 (StataCorp, College Station, TX, USA).
Results
Patient characteristics
The NCDB database yielded 51 patients with 58.8  % 
(n  =  30) males. Median age was 60  years (IQR 
49–72  years). Clinical characteristics of the patients are 
shown in Table 1.
Fig. 1 Search strategy for selecting studies for the systematic review
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Tumor characteristics
Median tumor size was 16  cm (IQR 11–21  cm) and 
68.6 % of tumors were 10 cm or larger. When separated 
by tumor grade, 9.8 % (n = 5) were undifferentiated/ana-
plastic. Well-differentiated, moderately differentiated and 
poorly differentiated tumors were present in equal pro-
portion of 11.8 % (n = 6). Distant metastases were pre-
sent at diagnosis in 9.1 % (n = 4) of tumors.
Surgical treatment
Surgical excision was recorded in 92.2  % (n  =  47) of 
patients. Among 35 patients with recorded surgical 
margins, microscopically negative (R0) accounted for 
63.8  % (n  =  30), microscopically positive (R1) in 4.3  % 
(n  =  2) and gross positive (R2) in 6.4  % (n  =  3). Peri-
operative mortality was 2.1 % (n = 1). Unplanned read-
missions within 30  days of surgery were observed in 
8.5 % (n = 4) of patients.
Chemotherapy and radiation therapy
Peri-operative radiation therapy was given to 31.4  % 
(n =  16) of patients (3 neo-adjuvant, 13 adjuvant). Of the 
19.6 % (n = 10) patients who received chemotherapy, 15.6 % 
(n = 8) were peri-operative (3 neo-adjuvant, 5 adjuvant) and 
Table 1 Baseline characteristics and  therapies of  solitary fibrous tumor (SFT) patients from  National Cancer Database 
(NCDB) and systematic review
a IQR inter-quartile range
b Percentages are calculated on the number of patients who had surgery for the tumor
Characteristic NCDB (51 pts) Systematic review (24 pts)
Median (IQR)a Frequency N (%) Median (IQR)a Frequency N (%)
(Age (years) 60 (49–72) 47.5 (39–66.5)
Gender
 Male 30 (58.8) 14 (58.3)
 Female 21 (41.2) 10 (41.7)
Tumor size (cm) 16 (11–21) 12 (7–17)
 <10 cm 12 (23.5) 7 (29.2)
 ≥10 cm 35 (68.6) 11 (45.8)
Tumor grade
 Well-differentiated 6 (11.76)
 Moderately differentiated 6 (11.76)
 Poorly differentiated 6 (11.76)
 Undifferentiated/anaplastic 5 (9.8)
Distant metastasis at diagnosis 4 (9.09)
Surgery 47 (92.2) 22 (91.7)
Surgical marginsb
 Negative (R0) 30 (63.8)
 Microscopic positive (R1) 2 (4.3)
 Gross positive (R2) 3 (6.4)
 Unknown 12 (25.5)
Unplanned 30-day readmissionb 4 (8.5)
30-day mortalityb 1 (2.1)
Radiation therapy 16 (31.4)
 Adjuvant 13 (25.5)
 Neo-adjuvant 3 (5.8)
Chemotherapy 10 (19.6) 1 (4.2)
 Adjuvant 5 (9.8)
 Neo-adjuvant 3 (5.8)
 Systemic 2 (3.9)
Combination therapy 4 (7.8)
Late recurrences 4 (16.7)
Follow-up (months) 45.2 (30.3–63.3) 54 (28–144)
Mortality at last follow-up 10 (19.6) 3 (12.5)
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3.9 % (n = 2) did not undergo surgery. Both chemotherapy 
and radiation therapy were given to 7.8 % (n = 4) patients.
Survival analysis
Of the 18 patients with vital status recorded, median fol-
low-up was 45.2  months (IQR 30.3–63.3  months) and 
overall median survival was 51.1  months (IQR 30.3–
63.3  months). 10 patients died of disease with a median 
follow-up of 34.0 months, while 8 were alive with a median 
follow-up of 64.9  months. When stratified by therapy, 
median survival was not reached in patients undergoing 
surgery alone. Among patients with surgery and chemo-
therapy alone, only one patient had follow-up data.
Of the three patients who had both surgery and radia-
tion and had follow-up data all three died with a median 
survival of 51.1  months (IQR 24.5–58.5  months). 
Median survival of patients undergoing surgery, chemo-
therapy and radiotherapy was 69.2  months (IQR 20.5–
118 months) (Table 2). One patient who received surgery 
and chemotherapy alone died at 23 months.
Results of systematic review
The search strategy resulted in 55 articles of which 8 
satisfied the inclusion criteria, with a total of 24 cases 
(Fig. 1; Table 3). 47 articles were excluded from the final 
analysis because these were published in non-English 
language, or were single patient case reports or were 
available as abstracts only. Median age was 47.5  years 
(IQR 39–66.5  years) and 58.3  % (n  =  14) were male 
(Table  1). Mean tumor size was 12  cm (IQR 7–17  cm). 
Two of the identified cases were originally diagnosed as 
hemangiopericytomas while one was identified as deep 
fibrous histiocytoma. Of 21 cases with CD34 status 
available, 19 were positive. Similarly 12 cases were bcl-2 
positive (of 12 avaialble reports) and 6 CD99 positive 
(of 7 available reports). 91.7 % (n =  22) patients under-
went surgical excision (1 patient had positive surgical 
margins), while 1 patient also received adjuvant chemo-
therapy. Of the remaining two patients, only biopsies 
were performed for one case as multiple comorbidities 
precluded surgical excision and treatment information 
was not available in one patient. Median follow up was 
54 months (IQR 28–144 months). Late recurrences were 
reported in 16.7  % (n =  4) cases (2 local and 2 distant 
recurrences). Recurrence free survival (RFS) ranged from 
1 to 288 months. At last follow-up date, 79.2 % (n = 19) 
patients were alive without disease, 4.2  % (n  =  1) alive 
with disease, 12.5 % (n = 3) died of the disease and one 
patient was lost to follow-up. Two of the deaths had late 
recurrences and one died within 30 days of surgery with a 
positive surgical margin.
Discussion
In our study, we analyzed 51 cases of retroperitoneal 
SFTs from the National Cancer Database on their treat-
ment modality and outcomes and compared it to pub-
lished literature on retroperitoneal SFTs. To the authors’ 
best knowledge, this is the largest and most comprehen-
sive series on retroperitoneal SFTs till date and the first 
study to conduct a formal analysis of surgical outcomes. 




Median overall survival (months) 51.1 (30.3–63.3)
Median survival (months)
 Surgery alone (n = 10)
 Surgery + chemotherapy (n = 1)
 Surgery + radiotherapy (n = 3) 51.1 (24.5–58.5)
 Surgery + chemotherapy + radiotherapy (n = 2) 69.2 (20.5–118)
Table 3 Summary of studies selected for literature review
a Adjuvant chemotherapy was given to one of the patients
b One patient was lost to follow-up
c Patient died within 30 days of surgery
Authors Year N Average tumor  
size (cm)




Decouvelaere et al. [9] 1998 3 10.5 120 12–168
Hasegawa et al. [3] 1999 8 10.25 57
Morimitsu et al. [36] 2000 1 23 32
Guillou et al. [37] 2000 3 18.17 39b
Clayton et al. [35]a 2001 2 10 36
Takizawa et al. [6] 2007 4 15.9
Mosquera et al. [17] 2009 1 20 1c
Baldi et al. [2] 2013 2 228 156–276
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Based on our study, surgery is a valid standard therapy 
for retroperitoneal SFTs.
Peri-operative morbidity and mortality rates were com-
parable with other retroperitoneal sarcomas [15, 16]. 
When stratified by therapy median survival of patients 
who underwent surgery and chemotherapy and radiation 
therapy was higher than patients with surgery and radi-
otherapy alone but it carries no statistical significance 
as the former group consisted of four patients of which 
follow-up information was available only for two. The 
efficacy of chemotherapy in retroperitoneal SFTs is ques-
tionable. When compared to patients who did not receive 
chemotherapy, chemotherapy group had a larger mean 
tumor size (18.2  cm vs. 15.8  cm), higher grade (40  % 
poorly differentiated/undifferentiated vs. 17 %) and more 
positive resection margins (20 vs. 17  %) and this might 
have confounded the results.
Retroperitoneal SFTs are different from other SFTs in 
their larger size at presentation. Retroperitoneal SFTs are 
mostly asymptomatic or present with vague non-specific 
symptoms of abdominal pain, increase in abdominal 
girth, weight loss and are often diagnosed incidentally 
when imaging for unrelated conditions, while SFTs of 
pleura, extremities and other sites present with signs and 
symptoms of mass lesion or are visible to the patient and 
is likely to be diagnosed early in their course [17]. Thus, 
the larger size at presentation could be explained by the 
delay in diagnosis due to lack of specific symptoms. Pre-
vious studies have reported a larger tumor size (>10–
15  cm) as a predictor of worse outcome for metastasis 
[10, 18, 19]. Also, size greater than 10 cm is a component 
of England criteria for classifying SFTs into malignant 
and benign [5].
Management of retroperitoneal SFTs is not clearly 
defined. Data is lacking on treatment strategies owing 
to the orphan status of the tumor. Current therapy is 
drawn from data on therapy outcomes in similar tumors. 
Surgery is the standard treatment modality for retro-
peritoneal SFTs. A positive resection margin has been 
correlated with worse local recurrence free survival and 
metastasis free survival by Gold et  al. and with local 
recurrence by van Houdt et al. [10, 19]. However, Wilky 
et al. has found no association of resection margins with 
recurrence and instead reported an association with 
malignant histology suggesting that histology may have 
confounded the association [20]. Regardless, the authors 
feel that it is safe to keep a high index of suspicion for 
recurrence in any tumor with positive resection margins 
as all the deaths due to disease in the systematic review 
had positive resection margins while all of the alive 
patients had negative margins. Recurrence rates in retro-
peritoneal SFTs are low compared to other retroperito-
neal sarcomas (17 vs. 52–61 %) [15, 16]. This might argue 
against routine use of therapies to reduce recurrence rate 
unless validated by further evidence. However, the use 
of radiation therapy in the treatment of extra-abdominal 
SFT has been documented in case series with anecdotal 
effectiveness [2, 10].
The rates of peri-operative morbidity and mortality 
in NCDB data was minimal. Wignall et al. has reported 
technical complexity of the surgery due to the vascular 
nature of the tumor and the presence of collateral feeding 
vessels and recommends referral to a tertiary care center 
and use of techniques like embolization before surgery 
[21].
Solitary fibrous tumors may recur even after a pro-
longed latent period and retroperitoneal SFTs are no 
exception, as three of the recurrences in the review 
occurred after 10  years of surgery for primary tumor, 
as echoed by previous reports [9, 10, 18]. Furthermore, 
intra-abdominal and retroperitoneal SFTs have been 
reported to have a higher recurrence rate compared to 
extra-abdominal tumors [11]. These observations war-
rant a prolonged follow-up and surveillance for retro-
peritoneal SFTs. The authors recommend a minimum 
follow-up of 15 years with prolonged follow-up intervals 
after first 3 years.
The diagnosis of retroperitoneal SFTs requires his-
tologic confirmation. The lack of a uniform nomencla-
ture system in the past had led to SFTs being identified 
as localized fibrous tumor, localized fibrous mesothe-
lioma, solitary fibrous mesothelioma, fibrous mesothe-
lioma, subserosal fibroma and submesothelial fibroma 
[22]. Also, the absence of sensitive and specific markers 
and the nonspecific histologic pattern of the tumor pro-
hibited an accurate diagnosis. However recent investi-
gations into the genetics of the tumor has revealed the 
overexpression of STAT6 protein, a result of gene-fusion 
on chromosome 12q13 which leads to a NAB2-STAT6 
fusion product. A highly sensitive and specific marker for 
SFTs has been developed based on a nuclear staining test 
for the STAT6 protein solving the diagnostic conundrum 
[23–26]. SFTs can be divided into benign and malignant 
categories based on its histological features, namely 
hyper cellularity, pleomorphism, necrosis/hemorrhage 
and mitoses (>4 mf/10 hpf). Different criteria have been 
developed to assign malignant or benign classifica-
tion to SFTs based on histologic features, age, location, 
size, sessile/pedunculated nature [5, 18]. Nevertheless, 
SFTs classified as benign have been observed to undergo 
malignant transformation and recur at local and distant 
sites [8, 9, 12, 17, 27]. In view of this unpredictable behav-
ior and the increased risk of retroperitoneal SFTs to recur 
than other SFTs, it is judicious to follow-up all cases of 
retroperitoneal SFTs irrespective of satisfying the criteria 
for benign tumors.
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The treatment of recurrent SFTs is evolving. The 
uncommonness of the tumor prohibits a prospective 
trial. Anti-angiogenic drugs have been tried considering 
the vascular nature of the tumor. Interferon-alfa and bev-
acizumab–temozolomide combination has shown prom-
ise in disease stabilization in recurrent cases [28–30]. 
Tyrosine kinase inhibitors(TKI)s are another set of drugs 
being investigated for malignant and aggressive SFTs. 
Sunitinib, pazopanib and regorafenib has been shown 
to be efficacious in animal models and has been studied 
retrospectively [31–33]. Conventional chemotherapeutic 
agents like dacarbazine also has been shown to be effec-
tive against SFTs [28, 33]. Prospective studies on dacar-
bazine, TKIs and other investigational drugs are being 
conducted currently. Park et  al. recommends targeted 
therapies/antiangiogenic drugs initially and stabilizing 
the disease later with conventional chemotherapy [34].
Given the rarity of solitary fibrous tumors of the retro-
peritoneum, studies that describe the management and 
outcomes of these tumors are limited in number. Avail-
able literature is focused on SFTs in the pleura due to its 
more common occurrence. Previous studies on retrop-
eritoneal SFTs are mostly case reports and outcomes of 
surgery have not been studied.
Our study was limited by the number of cases, both in 
the NCDB registry and published literature. Number of 
patients was insufficient to perform a multi-variate sub-
group analysis. Past studies on SFTs were heterogeneous 
in their reporting of surgeries. Treatment of recurrences 
was not recorded in some instances. The ambiguous 
pathologic terminology in practice for describing SFTs 
makes it possible that many tumors were misclassified 
and as a result not included in the literature review as 
our search strategy did not consider all available terms 
for SFTs. Three of the studies in the systematic review 
were from the United States and one of them is from 
a National Cancer Institute designated cancer center 
and this may lead to an overlap of two patients with the 
NCDB data [35].
Conclusions
Considering the orphan status of solitary fibrous tumors, 
it is impossible to conduct a study involving adequate 
number of cases. In this scenario, our analysis of NCDB 
and systematic review of published literature demon-
strates that surgical excision is a feasible and reasonable 
first line of therapy for retroperitoneal solitary fibrous 
tumors with minimal perioperative morbidity and mor-
tality and overall median survival above 4  years. The 
diagnosis may be confirmed by novel nuclear stain-
ing techniques if in doubt. For recurrent and aggressive 
tumors, a multimodality therapy incorporating surgery, 
chemotherapy and radiotherapy may be considered on a 
case to case basis. Anti–angiogenic drugs and TKIs are 
appropriate for initial therapy and conventional chemo-
therapy may be used later to stabilize the disease and the 
patient could be enrolled in ongoing clinical trials. Given 
the propensity for late recurrences even in clinically and 
histologically benign tumors, SFTs should be followed up 
for a prolonged period of 15 years, irrespective of nature 
of the tumor at initial presentation.
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